Tag: Myocardial Infarction
-
Shorter Dual Antiplatelet Therapy Benefits for Myocardial Infarction Patients
Recent findings have cast a new light on dual antiplatelet therapy (DAPT) in the context of myocardial infarction (MI). For years, the standard protocol for post-MI management has included a prolonged duration of dual antiplatelet therapy—typically around 12 months. However, emerging evidence suggests that a shorter duration of therapy, specifically three months, may offer significant…
-
Shorter Dual Antiplatelet Therapy for Myocardial Infarction Patients
Dual antiplatelet therapy (DAPT) is a cornerstone in the management of patients who have experienced a myocardial infarction (MI), commonly known as a heart attack. Traditionally, the standard duration for DAPT has been 12 months following an MI to prevent thrombotic events. However, recent clinical research suggests that a shorter duration of DAPT, specifically three…
-
Benefits of Shorter Dual Antiplatelet Therapy in Myocardial Infarction Patients
In the landscape of cardiovascular interventions, dual antiplatelet therapy (DAPT) has emerged as a cornerstone for patients who have experienced myocardial infarction (MI). Traditionally, a prolonged duration of DAPT, often reaching 12 months or more, was the norm. However, recent research has illuminated potential safety benefits associated with a shorter duration of treatment, specifically three…